An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Soleno Therapeutics, a clinical-stage biopharmaceutical company, announced the grant of inducement awards to six new employees, as required by Nasdaq rules. The options have an exercise price of $37.90 per share and will vest over a four-year period.
Soleno Therapeutics, un'azienda biofarmaceutica in fase clinica, ha annunciato l'assegnazione di premi di incentivo a sei nuovi dipendenti, come previsto dalle regole del Nasdaq. Le opzioni hanno un prezzo di esercizio di $37.90 per azione e matureranno nel corso di un periodo di quattro anni.
Soleno Therapeutics, una compañía biofarmacéutica en etapa clínica, anunció la concesión de premios de incentivo a seis nuevos empleados, según lo requieren las normas de Nasdaq. Las opciones tienen un precio de ejercicio de $37.90 por acción y se vestirán a lo largo de un período de cuatro años.
임상 단계의 바이오 제약 회사인 Soleno Therapeutics가 나스닥 규칙에 따라 새로운 직원 6명에게 인센티브 상을 부여했다고 발표했습니다. 옵션의 행사 가격은 주당 $37.90이며, 4년 동안 귀속됩니다.
Soleno Therapeutics, une entreprise biopharmaceutique en phase clinique, a annoncé l'attribution de primes d'incitation à six nouveaux employés, conformément aux règles du Nasdaq. Les options ont un prix d'exercice de 37,90 $ par action et seront acquises sur une période de quatre ans.
Soleno Therapeutics, ein biopharmazeutisches Unternehmen in der klinischen Phase, gab die Gewährung von Anreizpreisen an sechs neue Mitarbeiter bekannt, wie von den Nasdaq-Regeln gefordert. Die Optionen haben einen Ausübungspreis von $37.90 pro Aktie und werden über einen Zeitraum von vier Jahren vestiert.
Positive
None.
Negative
None.
REDWOOD CITY, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to six new employees.
The independent members of the Board of Directors of Soleno approved the grant of non-qualified stock options to purchase 96,500 shares of common stock to six employees as an inducement for them entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $37.90 per share, which is equal to the closing price of Soleno’s common stock on the Nasdaq Stock Market on April 17, 2024, the date of grant. The option award will vest over a four-year period, with 25% of the shares subject to the award vesting on the one-year anniversary of the date of grant, and thereafter an additional 1/48th of the shares subject to the award vesting on each succeeding monthly anniversary of the date of grant, subject to such employee’s continued employment with Soleno through such vesting dates. The option awards are subject to the terms and conditions of Soleno’s existing 2020 Inducement Equity Incentive Plan and the terms and conditions of the stock option covering the grant.
About Soleno Therapeutics, Inc. Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR (Diazoxide Choline) extended-release tablets, a once-daily oral tablet for the treatment of PWS, recently completed its Phase 3 development program to support a planned NDA submission. For more information, please visit www.soleno.life.
Corporate Contact: Brian Ritchie LifeSci Advisors, LLC 212-915-2578
FAQ
What did Soleno Therapeutics announce regarding inducement grants?
Soleno Therapeutics announced the grant of inducement awards to six new employees in accordance with Nasdaq Listing Rule 5635(c)(4).
How many shares of common stock were granted to the employees?
The employees were granted non-qualified stock options to purchase 96,500 shares of common stock.
What is the exercise price of the options?
The exercise price of the options is $37.90 per share.
How will the options vest?
The options will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the grant date, and an additional 1/48th of the shares vesting on each succeeding monthly anniversary.
soleno therapeutics, inc. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. the company is currently advancing its lead candidate, dccr, a once-daily oral tablet for the treatment of pws, into a phase iii clinical development program in early 2018.
